OPRX vs. RMNI, ZFOX, DHX, STCN, MCHX, EGIO, EEX, RGP, ZH, and LQDT
Should you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include Rimini Street (RMNI), ZeroFox (ZFOX), DHI Group (DHX), Steel Connect (STCN), Marchex (MCHX), Edgio (EGIO), Emerald (EEX), Resources Connection (RGP), Zhihu (ZH), and Liquidity Services (LQDT). These companies are all part of the "business services, not elsewhere classified" industry.
OptimizeRx (NASDAQ:OPRX) and Rimini Street (NASDAQ:RMNI) are both small-cap computer and technology companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, community ranking, risk and dividends.
76.5% of OptimizeRx shares are owned by institutional investors. Comparatively, 73.8% of Rimini Street shares are owned by institutional investors. 4.4% of OptimizeRx shares are owned by company insiders. Comparatively, 41.3% of Rimini Street shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
OptimizeRx has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Rimini Street has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.
In the previous week, OptimizeRx had 2 more articles in the media than Rimini Street. MarketBeat recorded 4 mentions for OptimizeRx and 2 mentions for Rimini Street. Rimini Street's average media sentiment score of 1.86 beat OptimizeRx's score of 0.41 indicating that Rimini Street is being referred to more favorably in the news media.
OptimizeRx currently has a consensus target price of $15.86, indicating a potential upside of 50.45%. Rimini Street has a consensus target price of $4.50, indicating a potential upside of 93.97%. Given Rimini Street's higher possible upside, analysts clearly believe Rimini Street is more favorable than OptimizeRx.
Rimini Street has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks.
Rimini Street has a net margin of 5.02% compared to OptimizeRx's net margin of -24.56%. OptimizeRx's return on equity of -7.72% beat Rimini Street's return on equity.
Rimini Street received 11 more outperform votes than OptimizeRx when rated by MarketBeat users. Likewise, 63.49% of users gave Rimini Street an outperform vote while only 62.83% of users gave OptimizeRx an outperform vote.
Summary
Rimini Street beats OptimizeRx on 12 of the 18 factors compared between the two stocks.
Get OptimizeRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptimizeRx Competitors List
Related Companies and Tools
